

Amendment to the Claims

Claims 1-7 (Canceled)

8. (Currently Amended) A transgenic mouse whose genome comprises a homozygous disruption in the Cer1 gene, said disruption comprising replacement of nucleotides corresponding to bases 241 through 528 of SEQ ID NO:1 with a Neo cassette~~gene comprising the nucleotide sequence of SEQ ID NO: 1, wherein said transgenic mouse exhibits, relative to a wild-type mouse, increased anxiety.~~

Claims 9-16 (Canceled)

17. (Currently amended) The transgenic mouse of claim 1 wherein said mouse exhibits further exhibiting anti-depressive behavior and/or hypoactivity.
18. (New) The transgenic mouse of claim 1 wherein said mouse is homozygous for said disruption.
19. (New) The transgenic mouse of claim 18 wherein said mouse exhibits in the open field test, decreased average velocity and decreased total distance traveled, relative to a wild-type control mouse.
20. (New) The transgenic mouse of claim 19 wherein said mouse exhibits hypoactivity.
21. (New) The transgenic mouse of claim 18 wherein said mouse exhibits in the tail suspension test, decreased total time spent immobile, relative to a wild-type control mouse.
22. (New) The transgenic mouse of claim 18 wherein said mouse exhibits in the open field test, increase in the number of fecal boli, relative to a wild-type control mouse.
23. (New) The transgenic mouse of claim 22 wherein said mouse exhibits increased fear, anxiety or nervousness.